Login to Your Account



Forest Gets PADAC Vote, but No Gold Stars for COPD Drug

By Mari Serebrov
Washington Editor

Friday, February 24, 2012
Forest Laboratories Inc. got hesitant, but positive, support Thursday for approval of its inhaled aclidinium bromide as a twice-daily treatment for bronchospasms associated with chronic obstructive pulmonary disease (COPD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription